The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma
Open accessAbstract
BACKGROUND.: Bisphosphonates (BPs) are effective in the prevention and treatment of skeletal‐related events (SREs) in patients with symptomatic myeloma who are receiving chemotherapy. Recent data also suggest a possible antineoplastic activity of BPs. Few studies published to date have explored the role of BPs in patients with untreated, asymptomatic myeloma (AM). No data are available on the efficacy of zoledronic acid in these patients. METHODS.: The authors conducted a prospective, multicenter, open‐label, phase 3, randomized trial comparing the administration of zoledronic acid versus simple observation in patients with AM. One‐hundred sixty‐three patients were enrolled and randomized (1:1) to receive zoledronic acid (n = 81 patients) or not to receive zoledronic acid (n = 82 patients) for 1 year at a dose of 4 mg monthly as a single, 15‐minute, intravenous infusion. RESULTS.: After a median follow‐up of 64.7 person‐months, 44.4% of patients in the zoledronic acid group and 45.1% of the control group progressed to ‘symptomatic’ myeloma requiring chemotherapy ( P = .9307). The median time to progression was 67 months and 59 months for the treatment and control groups, respectively ( P = .8312). At progression, SREs were significantly lower in the zoledronic acid‐treated group (55.5%) than in the control group (78.3%; P = .041), whereas anemia, renal failure, and extramedullary disease were not statistically different. More frequent adverse events observed in the zoledronic acid‐treated group were asymptomatic hypocalcemia and fever. One patient developed reversible osteonecrosis of the jaw. No renal failure caused by zoledronic acid was reported. CONCLUSIONS.: The monthly use of zoledronic acid for 1 year in patients with AM reduced the development of SREs at progression but did not influence the natural history of the disease. Cancer 2008. © 2008 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma
Kyle, R. A., Remstein, E. D., Therneau, T. M., Dispenzieri, A., Kurtin, P. J., Hodnefield, J. M., Larson, D. R., Plevak, M. F., Jelinek, D. F., Fonseca, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070389 · Cited by 921
Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid.
Wood, J., Bonjean, K., Ruetz, S., Bellahcène, A., Devy, L., Foidart, J. M., Castronovo, V., & Green, J. R. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.035295 · Cited by 854
Hjorth, M., Hellquist, L., Holmberg, E., Magnusson, B., Rödjer, S., & Westin, J. (1993) · European Journal of Haematology · doi:10.1111/j.1600-0609.1993.tb00148.x · Cited by 220 · cited 1×
“with j/k 59/22 57/25 Median mo from diagnosis [range] 16 [0-39] 14 [0-42]”
Cited by
Khan, A. A., Morrison, A., Hanley, D. A., Felsenberg, D., McCauley, L. K., O'Ryan, F., Reid, I. R., Ruggiero, S. L., Taguchi, A., Tetradis, S., et al. (2015) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2405 · Cited by 1,353
Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma
Mateos, M.-V., Hernández, M.-T., Giraldo, P., de la Rubia, J., de Arriba, F., Corral, L. L., Rosiñol, L., Paiva, B., Palomera, L., Bargay, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1300439 · Cited by 1,171
Morgan, G. J., Davies, F. E., Gregory, W. M., Cocks, K., Bell, S. E., Szubert, A. J., Navarro-Coy, N., Drayson, M. T., Owen, R. G., Feyler, S., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)62051-x · Cited by 575
Multiple myeloma current treatment algorithms
Rajkumar, S. V., & Kumar, S. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-00359-2 · Cited by 355
Terpos, E., Morgan, G., Dimopoulos, M. A., Drake, M. T., Lentzsch, S., Raje, N., Sezer, O., García-Sanz, R., Shimizu, K., Turesson, I., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.7901 · Cited by 352
Metadata
- Authors
- Musto, P., Petrucci, M. T., Bringhen, S., Guglielmelli, T., Caravita, T., Bongarzoni, V., Andriani, A., D'Arena, G., Balleari, E., Pietrantuono, G., Boccadoro, M., & Palumbo, A.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2008-08-05
- Volume
- 113
- Issue
- 7
- Pages
- 1588-1595
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2082853777
- Cited by
- 185
- References
- 3
- FWCI
- 6.01
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma. https://app.cochat.ai/papers/10.1002/cncr.23783
- The paper
- Musto, P., Petrucci, M. T., Bringhen, S., Guglielmelli, T., Caravita, T., Bongarzoni, V., Andriani, A., D'Arena, G., Balleari, E., Pietrantuono, G., Boccadoro, M., & Palumbo, A. (2008). A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma. Cancer. https://doi.org/10.1002/cncr.23783
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.